Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading

In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated disease progression and tau spreading, yet the mechanisms underlying faster disease manifestation are unknown. To address this, we combined resting-state fMRI and longitudinal tau-PET in two independent samples of controls and biomarker-confirmed AD patients (ADNI/BioFINDER, n = 240/57). Consistent across both samples, we found that younger symptomatic AD patients showed stronger tau-PET in globally connected fronto-parietal hubs, i.e., regions that are critical for maintaining cognition in AD. Stronger tau-PET in hubs predicted faster subsequent tau accumulation, suggesting that tau in globally connected regions facilitates connectivity-mediated tau spreading. Further, stronger tau-PET in hubs mediated the association between younger age and faster tau accumulation in symptomatic AD patients, which predicted faster cognitive decline. These independently validated findings suggest that younger AD symptom onset is associated with stronger tau pathology in brain hubs, and accelerated tau spreading throughout connected brain regions and cognitive decline.

Sporadic Alzheimer’s disease (AD) is highly heterogeneous, with variable clinical expression, age of symptom onset as well as cognitive and neuropathological trajectories1–3. In sporadic AD, younger age of symptom onset has been previously associated with accelerated tau accumulation4–5 and neurodegeneration6, faster cognitive decline7–8 and higher mortality9, together suggesting that younger symptom onset is potentially driven by a more aggressive form of AD10. Yet, it is unclear why sporadic AD patients with younger symptom onset show faster pathological11–15 and clinical progression5–8 than patients with later symptom onset. From a histopathological point of view, non-mendelian early- and late-onset sporadic AD share the same molecular pathologies including amyloid-beta (Aβ) plaque and neurofibrillary tangles composed of hyperphosphorylated 3/4R tau pathology, suggesting that an earlier symptom onset is unlikely to be specifically
driven by distinct molecular characteristics of AD pathology\(^\text{11}\). Rather, previous post-mortem and tau-PET imaging studies reported that an earlier AD symptom onset is associated with a different spatial distribution pattern of tau pathology\(^\text{12,13}\), i.e., the key driver of neurodegeneration\(^\text{11}\) and cognitive decline in AD\(^\text{14,15}\). Specifically, post-mortem assessments in AD patients found that a more pronounced neocortical and hippocampal-sparing pattern of neurofibrillary tau pathology is associated with younger age and symptom onset and faster ante-mortem cognitive decline, whereas a spatially more restricted limbic-predominant pattern of neurofibrillary tau tangles was associated with older age at symptom onset and slower ante-mortem cognitive decline\(^\text{16}\). Similarly, tau-PET studies in AD patients found that younger age in general\(^\text{16,17}\) and early-onset AD (i.e., before the age of 65) in particular are associated with stronger tau-PET uptake in fronto-parietal association cortex regions\(^\text{18,19}\) with relative sparing of medial temporal lobe regions\(^\text{18}\). Together, these findings suggest that an earlier symptom onset in AD is associated with a pattern shift of tau pathology deposition from allocortical medial temporal lobe regions toward neocortical fronto-parietal association cortices. As shown by functional MRI studies, fronto-parietal brain regions harbor key hubs that are globally connected to the rest of the brain\(^\text{20,21}\) and central for cognitive function\(^\text{22}\), as they facilitate information integration across different brain networks during cognitive demands\(^\text{22}\). In a series of resting-state fMRI studies, we and others could previously show that the functional integrity of fronto-parietal control network hubs is critically important for maintaining cognitive function in aging\(^\text{22}\), AD\(^\text{23-25}\) and other neurodegenerative diseases\(^\text{26}\). Since tau pathology has been shown to impair neuronal function\(^\text{27}\) and to drive neurodegeneration\(^\text{11}\), a stronger tau pathology load in fronto-parietal hub regions that are highly relevant for cognition may thus drive earlier symptom manifestation in AD. In addition, tau pathology deposition in globally connected hub regions may further accelerate the progression and spreading of tau pathology itself, which is in turn a strong driver of cognitive decline\(^\text{11}\). Specifically, preclinical studies have consistently shown that tau spreads trans-synaptically across interconnected neurons\(^\text{11,12}\). Similarly, we and others reported previously in combined tau-PET and MRI studies that tau spreads preferentially across functionally and anatomically connected brain regions, where the connectivity pattern of tau harboring epicenter regions determines the subsequent spreading pattern of tau pathology\(^\text{37-39}\). Thus, the occurrence of tau pathology in globally connected hubs early in the course of AD may ensue faster and more widespread tau spreading thereby driving earlier disease manifestation and faster clinical progression\(^\text{38-44}\).

To address these open questions, the major aims of the current combined tau-PET and resting-state fMRI study were to assess whether: (1) younger age is associated with stronger tau pathology in globally connected hub regions compared to non-hubs in patients with symptomatic AD; (2) whether tau pathology in hub regions is associated with accelerated subsequent tau spreading and; (3) whether the association between younger age and faster tau accumulation rates in symptomatic AD\(^\text{45}\) is mediated by stronger tau pathology in globally connected hub regions. To this end, we employed two independent samples covering the entire AD spectrum, including 240 participants of the Alzheimer’s disease neuroimaging initiative (ADNI) and 57 subjects of the BioFINDER study for replication, all with available baseline amyloid-PET and longitudinal Flortaucipir tau-PET. To map the topology of globally connected hubs across the brain, we used high-resolution resting-state fMRI data from 1000 healthy participants of the human connectome project (HCP). Based on these resting-state fMRI data, we estimated an atlas-based\(^\text{46}\) whole-brain map of the graph-theoretical metric weighted degree (i.e., also referred to as global connectivity)\(^\text{47}\) in healthy individuals that are unaffected by AD pathology. By mapping individual tau-PET patterns in AD patients to the topology of globally connected brain hubs, we determined the degree to which individual tau-PET patterns are expressed in globally connected hub regions in the fronto-parietal association cortex vs. weakly connected non-hub regions e.g., in tempo-parietal and visual cortex region. Based on these data, we show that (1) individual tau-PET deposition patterns are indeed stronger in globally connected hub regions in younger patients with symptomatic AD and associated with earlier symptom onset; (2) that a more hub-like pattern of tau pathology deposition at baseline is associated with accelerated subsequent annual tau accumulation and; (3) that the association between younger age and faster tau accumulation rates in symptomatic AD is mediated by a more hub-like tau-PET pattern thereby driving faster cognitive decline.

**Results**

To address and validate the aims of the current study, we included two fully independent samples (ADNI and BioFINDER) with baseline amyloid-PET and longitudinal Flortaucipir tau-PET. We further included longitudinal cognitive data for a memory composite as well as age of symptom onset estimates in symptomatic AD patients which were available for a subset in ADNI. Both samples included cognitively normal (CN) control subject without evidence of AD pathology (ADNI/BioFINDER, n = 93/16), CN amyloid-positive individuals (i.e., preclinical AD, ADNI/BioFINDER, n = 60/16) and patients with symptomatic AD (i.e., mild cognitively impaired (MCI) and AD dementia; ADNI/BioFINDER, n = 89/25). Subject demographics for both samples are displayed in Table 1. Resting-state fMRI data from 1000 HCP participants was used to estimate a healthy connectivity template for the Schaefer 200 ROI atlas that covers the neocortex (Fig. 1A)\(^\text{39}\). Across the 1000 HCP participants, we created a group-average functional connectivity matrix, which was density thresholded at 30% to eliminate potentially weak and noisy connections and transformed to connectivity-based distance (i.e., higher functional connectivity = shorter connectivity-based distance, Fig. 1B). For each ROI, we then determined the mean connectivity-based distance to the remaining ROIs as a measure of hub-ness (i.e., shorter distance to the rest of the brain = higher hub-ness, Fig. 1C), which is equivalent to the graph theoretical measure weighted degree. In line with previous studies\(^\text{48}\), hub regions were primarily found in the fronto-parietal association cortex. To determine a hub map that scales brain regions between hubs and non-hubs, the group-average global connectivity map (Fig. 1C) was rescaled between 1 (i.e., hub) and -1 (i.e., non-hub) (Fig. 1D), in order to assess in a later step whether individual tau-PET patterns matched a hub or non-hub pattern. Tau-PET SUVR data (i.e., intensity normalized to the inferior cerebellar gray) was parcellated using the same 200 ROI parcellation (Fig. 1A), and pre-established two-component Gaussian mixture modeling (Fig. 1E) was applied to transform tau-PET SUVRs to tau-PET positivities in order to separate off-target from on-target tau-PET binding\(^\text{31}\). In an additional exploratory step, we also included tau-PET SUVRs from pre-established hippocampal ROIs\(^\text{49}\), which exclude the choroid plexus and therefore minimize the influence of Flortaucipir off-target binding. As for the remaining cortex, hippocampal tau-PET SUVRs underwent two-component Gaussian mixture modeling to further reduce the effect of off-target binding. Surface renderings of baseline tau-PET positivity across diagnostic groups are shown in Fig. 1F for ADNI and for BioFINDER, showing no evidence for tau-PET positivity in amyloid-negative controls, minimally elevated temporal-lobe tau levels in preclinical AD, vs. gradually increasing tau-PET positivity across symptomatic AD patients with MCI and AD dementia.

**Younger age is associated with a more hub-like tau-PET pattern in symptomatic AD**

To assess the degree to which individual tau-PET deposition represented a hub or non-hub pattern, we mapped patient-specific tau-PET positivity to the scaled hub map shown in Fig. 1D. Specifically, we multiplied ROI-specific subject-specific tau-positivity with the scaled
hub map shown in Fig. 1D, in order to determine hub-weighted tau positivity values, which were subsequently averaged and divided by the overall tau-PET positivity averaged across all 200 ROIs, to adjust for global tau deposition. We specifically adjusted for global tau levels, so that the tau hub ratio specifically reflected the pattern of tau deposition and not the overall tau severity. The mapping of subject-specific tau-PET patterns to the scaled hub map is illustrated in Fig. 1G–M, yielding a numeric index (i.e., henceforth referred to as tau hub ratio) that indicates whether a subject-specific tau-PET pattern is more representative of hub regions (i.e., more positive) or non-hub regions (i.e., more negative), while adjusting for global tau-PET positivity and not the overall tau severity. The mapping of subject-specific tau-PET patterns to the scaled hub map is illustrated in Fig. 1G–M, yielding a numeric index (i.e., henceforth referred to as tau hub ratio) that indicates whether a subject-specific tau-PET pattern is more representative of hub regions (i.e., more positive) or non-hub regions (i.e., more negative), while adjusting for global tau-PET positivity.

Using an ANOVA, no difference in the tau hub ratio was found between age of onset and the tau-PET acquisition date, sex, education and diagnosis. In addition, we tested whether the epicenters of tau pathology (i.e., 10% of brain regions with highest baseline tau-PET positivity) were more likely to be located in more globally connected regions in younger symptomatic AD patients (see Supplementary Table 1). In contrast, no association between age and the tau hub ratio was detected for asymptomatic patients with preclinical AD (ADNI: β = 0.087, p = 0.542, Fig. 2A, left panel; BioFINDER: β = −0.307, p = 0.901, Fig. 2B, left panel), in which abnormal tau-PET signal was minimal. When repeating the above-described analysis with the actual age of cognitive symptom onset based on informant assessments (i.e., available in 77/89 symptomatic ADNI participants), we found congruent results, showing that younger age of symptom onset was associated with a higher tau hub ratio (β = −0.256, p = 0.024, Fig. 3A), using linear regression controlling for the time difference between age of onset and the tau-PET acquisition date, sex, education and diagnosis. In addition, we tested whether the epicenters of tau pathology (i.e., 10% of brain regions with highest baseline tau-PET positivity) were more likely to be located in more globally connected regions in younger symptomatic AD patients (see Supplementary Table 1). In contrast, no association between age and the tau hub ratio was detected for asymptomatic patients with preclinical AD (ADNI: β = 0.087, p = 0.542, Fig. 2A, left panel; BioFINDER: β = −0.307, p = 0.901, Fig. 2B, left panel), in which abnormal tau-PET signal was minimal. When repeating the above-described analysis with the actual age of cognitive symptom onset based on informant assessments (i.e., available in 77/89 symptomatic ADNI participants), we found congruent results, showing that younger age of symptom onset was associated with a higher tau hub ratio (β = −0.256, p = 0.024, Fig. 3A), using linear regression controlling for the time difference between age of onset and the tau-PET acquisition date, sex, education and diagnosis. In addition, we tested whether the epicenters of tau pathology (i.e., 10% of brain regions with highest baseline tau-PET positivity) were more likely to be located in more globally connected regions in younger symptomatic AD patients (see Supplementary Table 1). In contrast, no association between age and the tau hub ratio was detected for asymptomatic patients with preclinical AD (ADNI: β = 0.087, p = 0.542, Fig. 2A, left panel; BioFINDER: β = −0.307, p = 0.901, Fig. 2B, left panel), in which abnormal tau-PET signal was minimal. When repeating the above-described analysis with the actual age of cognitive symptom onset based on informant assessments (i.e., available in 77/89 symptomatic ADNI participants), we found congruent results, showing that younger age of symptom onset was associated with a higher tau hub ratio (β = −0.256, p = 0.024, Fig. 3A), using linear regression controlling for the time difference between age of onset and the tau-PET acquisition date, sex, education and diagnosis.

Table 1 | Subject demographics

| ADNI (n = 240) | CN Aβ− (n = 93) | CN Aβ+ (n = 60) | MCI Aβ+ (n = 56) | AD dementia (n = 31) | p value |
|---------------|----------------|----------------|----------------|---------------------|---------|
| Age (M/SD)    | 72.54 (6.84)   | 75.23 (6.65)   | 75.14 (7.63)   | 76.87 (7.74)        | 0.011   |
| Sex (m/f)     | 39/54          | 26/34          | 29/27          | 20/11               | 0.134   |
| Education (M/SD) | 16.51 (2.48)   | 16.6 (2.24)    | 16.25 (2.56)   | 15.9 (2.68)         | 0.568   |
| MMSE (M/SD)   | 29.21 (0.91)   | 28.78 (1.78)   | 27.33 (1.92)   | 21.75 (5.44)        | <0.001  |
| ADN+MEM (M/SD)| 1.11 (0.59)    | 0.87 (0.53)    | 0.2 (0.63)     | −0.77 (0.66)        | <0.001  |
| Centiloid (M/SD) | −3.62 (12.88)  | 69.62 (32.63)  | 76.72 (29.98)  | 89.28 (36.33)       | <0.001  |
| ApoE4 (pos/reg/NA) | 29/50/14       | 33/21/6        | 32/10/14       | 12/6/13             | <0.001  |
| Global tau-PET SUVR | 1.08 (0.08)   | 1.10 (0.09)    | 1.21 (0.22)    | 1.38 (0.41)         | <0.001  |
| Temporal meta ROI tau-PET SUVR | 1.12 (0.1)    | 1.15 (0.1)     | 1.29 (0.23)    | 1.43 (0.36)         | <0.001  |
| Tau hub gradient (M/SD) | −0.12 (0.16)  | −0.17 (0.17)   | −0.16 (0.19)   | −0.08 (0.24)        | 0.090   |
| Mean tau-PET follow-up time in years (M/SD) | 2.14 (1.12)   | 1.86 (0.71)    | 1.70 (0.83)    | 1.62 (0.61)         | <0.001  |
| BioFINDER (n = 57) | CN Aβ− (n = 16) | CN Aβ+ (n = 16) | MCI Aβ+ (n = 7) | AD dementia (n = 18) | p value |
| Age (M/SD)    | 73.88 (5.32)   | 75.44 (6.09)   | 72.71 (6.63)   | 69.83 (10.48)       | 0.192   |
| Sex (m/f)     | 10/6           | 6/10           | 2/5            | 11/7                | 0.245   |
| Education (M/SD) | 12.59 (4.06)   | 10.56 (3.22)   | 11.14 (2.67)   | 13.44 (3.26)        | 0.097   |
| MMSE (M/SD)   | 29 (1.1)       | 29.31 (1.08)   | 25.57 (2.94)   | 22.06 (5.17)        | <0.001  |
| Global Flutemetamol SUVR | 0.52 (0.03)  | 0.77 (0.12)    | 0.84 (0.14)    | 0.97 (0.15)         | <0.001  |
| ApoE4 (pos/reg/NA) | 0/16/0       | 10/6/0         | 4/3/0          | 10/7/1              | <0.001  |
| Global tau-PET SUVR | 1.04 (0.05)   | 1.05 (0.05)    | 1.37 (0.37)    | 1.49 (0.36)         | <0.001  |
| Temporal meta ROI tau-PET SUVR | 1.08 (0.06)   | 1.09 (0.05)    | 1.52 (0.39)    | 1.56 (0.31)         | <0.001  |
| Tau hub gradient (M/SD) | −0.16 (0.22)  | −0.09 (0.23)   | −0.15 (0.23)   | −0.06 (0.20)        | 0.566   |
| Mean tau-PET follow-up time in years (M/SD) | 2.03 (0.47)   | 1.91 (0.32)    | 1.82 (0.12)    | 1.97 (0.34)         | 0.484   |

p values were derived from ANOVAs for continuous measure sand from Chi-squared tests for categorical measures. M mean, SD standard deviation, m male, f female, MMSE mini-mental state exam, SUVR standardized uptake value ratio, NA not available.
Together, these results support the hypothesis that younger AD symptom onset is associated with stronger tau pathology in functional hub regions that are strongly interconnected with the rest of the brain.

In an exploratory analysis, we tested whether amyloid-positive ApoE4 non-carriers showed a stronger tau hub ratio, since previous work has suggested that ApoE4-carriage is associated with a more limbic-predominant pattern of tau pathology in AD patients\cite{16}, whereas amyloid-positive ApoE4 non-carriers show a more neocortical tau pathology pattern\cite{42}. Supporting this, we found that ApoE4-carriage was associated with a lower tau hub ratio in amyloid-positive (i.e., AD) patients (ADNI/BioFINDER: \( F = 4.816/4.404 \), Cohen’s \( d = 0.4/0.3 \), \( p = 0.002 \), Fig. 3B).
Younger age and a higher tau hub ratio are associated with faster tau accumulation in symptomatic AD

In a next step, we tested whether younger age was associated with a faster tau accumulation rate (i.e., annual change rate in global tau positivity) in patients with symptomatic AD. In line with previous work, we found that younger age was associated with a faster annual change rate in global tau-PET positivity in patients with symptomatic AD (ADNI: $\beta = -0.284$, $p = 0.009$, Fig. 4B, right panel; BioFINDER: $\beta = -0.386$, $p < 0.001$, Fig. 4C, right panel), using linear regression controlling for sex, education and diagnosis. As expected, no association between younger age and faster tau accumulation was detected in patients with preclinical AD (ADNI: $\beta = -0.119$, $p = 0.389$, Fig. 4B, left panel; BioFINDER: $\beta = 0.208$, $p = 0.448$, Fig. 4C, left panel), suggesting that faster tau accumulation or tau accumulation in general at younger age is specific for subjects with symptomatic AD. Next, we tested whether a higher tau hub ratio, indicating a more hub-like tau-PET deposition pattern, was associated with faster global tau accumulation. This analysis was motivated by our previous findings, showing that tau spreads from circumscribed epicenters to connected brain regions. Thus, tau pathology in a globally connected hub region should result in more widespread tau spreading and faster tau accumulation. In contrast, tau in only weakly interconnected non-
were generated using shuffled connectomes as a reference confirmed these results (ADNI: \( p = 0.010 \); BioFINDER: \( p = 0.018 \)). This result remained consistent when additionally controlling for age (ADNI: \( \beta = 0.259, p = 0.009 \); BioFINDER: \( \beta = 0.311, p = 0.026 \)), suggesting a unique contribution of the tau hub ratio to faster tau accumulation.

In patients with preclinical AD, we also found a significant association between a higher tau hub ratio at baseline and a faster subsequent tau accumulation rate in ADNI (\( \beta = 0.347, p = 0.006 \); Fig. 4D, left panel), controlling for sex and education, however this finding could not be replicated in BioFINDER (\( \beta = 0.199, p = 0.469 \); Fig. 4E, left panel). In summary, these results suggest that younger age and a more hub-like tau-PET retention pattern are associated with a faster accumulation of tau pathology in patients with symptomatic AD. Again, these results remained consistent when including hippocampal tau-PET (see Supplementary Table 2).

To further confirm that it is indeed the spatial distribution of tau pathology in hubs and not the overall severity of tau pathology that drives faster tau accumulation and earlier disease manifestation, we performed additional confirmatory analyses. Specifically, we conducted a sliding-window analysis from low to high global tau-levels analysis in AP+ subjects of ADNI and BioFINDER, and assessed for each window the mean annual tau-PET change and age, stratified by a high vs. low tau hub ratio (i.e., median split) or by high vs. low epicenter connectivity-based distance. We found significant interactions of global tau-PET and the tau hub ratio on the annual rate of tau accumulation (Supplementary Fig. 1A, B), where a higher tau hub ratio was associated with faster tau accumulation at higher baseline tau-PET levels. Similarly, we found an interaction between global tau-PET and the tau hub ratio on age in symptomatic AD patients, where a higher tau hub ratio was associated with younger age at higher tau-PET levels. These analyses support the view that a higher tau hub ratio is associated with faster tau accumulation at a given level of tau pathology in AD, as well as with younger age in symptomatic AD. Similarly, we found that at a given level of global tau-PET, more globally connected epicenters were associated with faster subsequent tau accumulation. Analyses are summarized in Supplementary Fig. 2A–F.

A higher tau hub ratio mediates the association between younger age and faster tau accumulation in symptomatic AD

Lastly, we assessed in symptomatic AD patients whether the effect of younger age on faster tau accumulation rates was mediated via stronger tau pathology in hub regions, i.e., a higher tau hub ratio. Using bootstrapped mediation analyses with 10,000 iterations, we found a significant mediation effect both in ADNI (\( \beta_{\text{adj}} = 0.063, 95\% \text{ CI} [-0.153; 0.00], p = 0.039 \)) and BioFINDER (\( \beta_{\text{adj}} = -0.149, 95\% \text{ CI} [-0.371; 0.00], p = 0.046 \)), controlling for sex, education and diagnosis. Mediation analyses are summarized in Fig. 5A, suggesting that a higher tau hub ratio mediates the association between younger age and faster tau accumulation rates in patients with symptomatic AD. These data remained consistent when also including hippocampal tau-PET (ADNI: \( \beta = -0.069, 95\% \text{ CI} [-0.164; -0.01], p = 0.024 \); BioFINDER: \( \beta = -0.149, 95\% \text{ CI} [-0.366; -0.01], p = 0.033 \)). Using longitudinal cognitive data available in symptomatic AD patients of the ADNI sample, we could further show that faster annual tau accumulation was associated with a faster decline in a memory composite (i.e., ADNI-MEM, \( \beta = -0.322, p = 0.004 \); Fig. 5B, controlling for age, sex and education), suggesting that faster tau hub ratio-dependent accumulation of tau pathology may drive faster clinical deterioration in younger patients with clinical AD. Again, this association remained consistent when including hippocampal tau-PET (\( \beta = -0.315, p = 0.004 \)). Confirming these analyses using the sliding-window approach introduced above, we found an interaction between baseline global tau-PET and the tau hub ratio on annual changes in ADNI-MEM, where a higher tau hub ratio was associated with faster cognitive decline at higher overall tau levels.
**Discussion**

The main findings of the current study were first, that younger patients with symptomatic AD show a more hub-like pattern of PET-assessed tau deposition, i.e., stronger tau in highly connected brain regions which are critical for domain-general cognition and which we have previously shown to be central for maintaining cognitive performance in AD.

Importantly, these associations were not detected for amyloid-positive, yet asymptomatic individuals (i.e., preclinical AD), in whom tau pathology was mostly absent. This supports previous findings of tau-pathology being a key driver of symptomatic disease manifestation in AD, while adding important new evidence that stronger tau deposition in globally connected hubs is associated with earlier AD symptom manifestation. Second, we found that younger age and a stronger load of tau pathology in globally connected hubs predicted faster subsequent tau accumulation rates in symptomatic AD patients which was associated with faster decline in memory performance. Connectivity is assumed to be a key mediator of tau spreading, hence these results favor the hypothesis that tau spreading facilitates tau spreading. A Schematic illustration of a hypothetical tau spreading model. When tau epicenters fall in a hub region with many connections to other regions, tau spread should be faster as compared to tau spread from an epicenter in a non-hub region with fewer connections. The association between age and annual tau-PET change rates for Aβ+ subjects is illustrated in B for the ADNI (N = 147) and C for the BioFINDER sample (N = 41), stratified by clinical status. Scatterplots showing the association the tau hub ratio and annual tau accumulation rates in D ADNI and E BioFINDER. β-values reflect standardized regression weights. All β- and two-sided p values were derived from linear regression controlling for sex, education (and diagnosis in symptomatic AD groups). Linear model fits (i.e., least squares line) are indicated together with 95% confidence intervals. Source data are provided as a Source Data file.
pathology in globally connected hubs early in the disease course may lead to more widespread propagation of tau pathology across connected brain regions, thereby driving faster cognitive deterioration in patients with earlier symptomatic AD manifestation\(^{14,15,30}\). To integrate our findings on how age, tau deposition patterns and tau accumulation rates are inter-related, we show that the association between younger age and faster tau accumulation in symptomatic AD patients is mediated by stronger tau pathology in hub regions. Together, the current independently validated findings provide key evidence that a pre-dilection of tau pathology deposition toward globally connected brain hubs that are crucial for cognition\(^2\) may determine earlier symptomatic disease manifestation and accelerate connectivity-mediated tau spreading.

For our first finding, we show that patients with younger symptomatic manifestation of AD show stronger tau pathology in globally connected hubs in the fronto-parietal association cortex compared to inferior temporal non-hubs (Fig. 2). This finding aligns well with previous post-mortem\(^{10}\) and in vivo tau-PET evidence\(^{12,13-19}\) showing that younger symptomatic AD onset is associated with a more neocortical limbic sparing tau pathology pattern, whereas older age of symptom onset is associated with a limbic-predominant tau pathology pattern\(^{10}\). Similarly, previous studies found that younger symptomatic AD onset is associated with stronger fronto-parietal gray matter atrophy\(^{3}\), hypoperfusion and glucose hypometabolism\(^{4,5}\), which have been shown to be closely associated with tau pathology in AD\(^3\). Together, this suggests that the spatial pattern rather than the mere extent of tau pathology may determine the likelihood, type and aggressiveness of symptom manifestation in AD\(^{12,17}\). The current findings critically extend these previous results by showing that younger symptomatic AD manifestation is specifically associated with a tau pathology pattern that resembles hub regions that are critical for domain general cognitive functioning\(^{21,22}\). Supporting a role of hubs for cognition in AD, we found previously that higher global connectivity fronto-parietal control network hubs such as the left frontal cortex is associated with a more efficient (i.e., small-world) global brain network topology\(^{10}\) and attenuated effects of posterior-cingulate glucose hypometabolism\(^{25}\), hippocampal atrophy\(^{41,42,50-52}\) or entorhinal tau pathology on cognitive performance\(^{25}\). This suggests that maintaining the integrity of hub regions may promote resilience to the impact of AD pathology on cognition\(^{10}\). In turn, damage to hub regions has been shown to diminish the efficient communication between brain networks\(^{3}\), and clinical studies in patients with cerebrovascular disease have shown that focal lesions in hubs cause brain-wide network disruptions\(^{39,40}\) and stronger impairment than lesions in non-hub regions\(^{5}\). Tau pathology has been shown to disrupt neuronal activity and connectivity in both preclinical\(^{38,39}\) and clinical studies\(^{35-38}\), hence early occurrence of tau pathology in hub regions may lead to an earlier impairment of global brain network function\(^{38}\) and thus earlier onset of cognitive impairment. Here, it will be an important next step to address whether higher tau pathology in hubs in fact drives a disruption of hub connectivity and thus an earlier symptom onset.

For our second finding, we could show that younger age and a stronger tau hub ratio are associated with faster tau accumulation in symptomatic AD. This is a critical extension of previous preclinical and clinical work, showing that brain connectivity mediates tau spreading\(^{34,35,59}\). Specifically, studies in mice and neuronal cell cultures found that tau spreads trans-synaptically, where higher synaptic activity facilitates tau spreading\(^{37,38}\). Similarly, we and others reported in combined MRI and tau-PET studies in AD patients that seed-based connectivity of tau harboring epicenters predict tau spreading patterns, where tau spreads preferentially from epicenters to connected regions\(^{13-17}\). Thus, a tau harboring hub region with widespread connections may potentiate tau spreading to connected regions compared to a non-hub with fewer connections (i.e., as illustrated in Fig. 4A). Supporting this, we found that younger symptomatic AD patients had regions of highest tau pathology (i.e., epicenters) in more globally connected brain regions and that a stronger tau hub ratio was associated with faster tau accumulation. Importantly, our findings also offer a mechanistic explanation for previous results on faster tau accumulation rates in younger AD patients\(^5\), which is further supported by our mediation analyses showing that the association between younger age and faster tau accumulation rates is mediated by a stronger tau hub ratio in symptomatic AD. Importantly, faster tau accumulation was associated with faster decline in memory performance, supporting the view that faster tau accumulation drives the rapid clinical progression in AD patients with earlier symptom manifestation\(^{13,18}\). Yet, we caution that these results on cognition were restricted to ADNI and warrant further validation in future studies. Nevertheless, our results suggest that hubs may play an important role as distributors of tau pathology, driving more widespread tau propagation and thus clinical deterioration. Of note, we also found an
association between the tau hub ratio and faster tau accumulation in preclinical AD patients in ADNI but not in BioFINDER, potentially since preclinical AD patients in ADNI already show slightly more advanced tau pathology than in BioFINDER (see Table 1) and may therefore be at higher risk of subsequent tau spreading.

For interpreting the results of the current study, several caveats should be taken into account. First, Flortaucipir tau-PET shows considerable off-target binding in subcortical regions including the hippocampus and basal ganglia. To address this, we excluded regions that are known to be severely affected by unspecific binding for our main analyses (e.g., hippocampus, basal ganglia) and further minimized any influence of Flortaucipir off-target binding by transforming tau-PET SUVRs to tau positivities using a Gaussian mixture modeling approach that has been previously applied by amyloid- and tau-PET studies to separate target- from unspecific binding. In an exploratory approach, we also included the hippocampus using a pre-established hippocampal mask that excludes the choroid plexus (i.e., the main source of off-target binding), yielding fully consistent results with our main analyses (see Supplementary Table 2). Still, it is possible that unspecific binding influences our results, hence our results await further replication using second-generation tau-PET data with a better off-target binding profile. Second, the current study included only a small number of patients that were clinically considered as early-onset AD (i.e., below the age of 65, ADNI/BioFINDER, n = 8/4). Therefore, the current study is mostly limited to the variability of tau deposition in the age range of typical late-onset AD. To specifically replicate the role of tau pathology in hubs in subjects with a clinical disease onset before the age of 65, we encourage future studies to assess whether our results can be replicated in dedicated early-onset AD datasets such as the LEADS cohort (https://clinicaltrials.gov/ct2/show/NCT03507257), once sufficient data become available. Third, the current study exclusively used weighted degree (i.e., global connectivity) as a measure of hub-ness, which yielded similar hub patterns as in previous studies. We specifically selected this measure, since it is relatively easy to interpret (i.e., strength of connectedness to the rest of the brain) and well-suited to test the effect of connectivity on tau spreading. We are, however, aware of the breadth of graph-theoretical measures that have been proposed to quantify the hub-ness of a given brain region, yet many of these measures are relatively abstract (e.g., betweenness-centrality, participation coefficient), and often highly intercorrelated. To avoid introducing additional and potentially redundant hub measures to an already complex set of analyses, we thus refrained from repeating the analyses with alternative measures of hub-ness. Fourth, other modulating factors such as reserve and resilience may influence symptom onset and progression rates in AD. To account for inter-individual differences in reserve and resilience, all analyses were statistically controlled for years of education, i.e., a well-established proxy of reserve and resilience in AD. However, we cannot exclude that inter-individual differences in reserve/resilience may further modulate symptom onset and progression rates. Lastly, we would like to highlight that we did not perform partial volume correction since longitudinal T1-weighted MRI data was not consistently available and since previous studies showed that longitudinal tau-PET changes can also be reliably detected without partial-volume correction.

In conclusion, our independently validated results provide novel evidence that younger symptomatic AD patients show stronger tau pathology in globally connected hubs, which may drive faster tau spreading and accelerated cognitive decline. This suggests that earlier symptom manifestation is not driven by specific pathophysiological characteristics, but rather by a tau distribution pattern that preferentially targets brain hubs important for cognitive function. These results converge well with previous findings, showing that heterogeneous tau distribution patterns are associated with heterogeneous clinical trajectories, variable symptom onset and disease progression. Here, it will be a key future goal to identify potential determinants of spatially variable tau pathology onset, such as differential gene expression patterns, pre-existing tau pathology (e.g., related to traumatic brain injury), or premorbid differences and/or heterogeneity in brain network architecture. Knowledge about drivers of tau onset, heterogeneous tau spreading patterns and clinical trajectories may become important to facilitate precision-medicine prediction of cognitive and pathological progression, as well as for patient stratification in clinical trials.

Methods

Participants—ADNI

We included 240 participants of the ADNI (ClinicalTrials.gov Identifier: NCT02854033) database. Inclusion criteria were availability of longitudinal 18F-Flortaucipir tau-PET as well as baseline 18F-Florbetapir or 18F-Florbetaben amyloid-PET, T1 MPRAGE structural MRI and demographic data. All baseline imaging had to be collected within 12 months. Aβ-status was assessed based on whole-cerebellum normalized global amyloid-PET SUVR, using pre-established protocols and cut-points (global AV45 SUVR > 1.1; global FBB SUVR > 1.08). Global amyloid-PET SUVRs were further transformed to the Centiloid scale to allow pooling across tracers. Clinical status was assessed by ADNI, categorizing subjects as CN (MMSE > 24, CDR = 0, non-depressed), MCI (MMSE > 24, CDR = 0.5, objective memory impairment on education adjusted Wechsler Memory Scale II, preserved activities of daily living), or demented (MMSE 20–26, CDR > 0.5, NINCDS/ADRDA criteria for probable AD). Amyloid-positive (n = 149) individuals were grouped as preclinical AD (i.e., CN, n = 60) or AD clinical syndrome (i.e., MCI [n = 57] and Dementia [n = 32]). Ethical approval was obtained by the ADNI investigators at each participating site, all participants provided written informed consent. All study relevant covariates are described in Table 1.

Participants—BioFINDER

As a replication sample, we included 57 BioFINDER (ClinicalTrials.gov Identifier: NCT01208675) participants with available Aβ-status, structural MRI and longitudinal 18F-Flortaucipir tau-PET. Baseline Aβ-status was determined using 18F-Flutemetamol PET as described previously, applying a pons-normalized global SUVR cut-off > 0.575. The Alzheimer’s center was covered by 16 CN Aβ+, 7 MCI Aβ+ and 18 AD dementia subjects vs. 16 CN Aβ- subjects as controls. BioFINDER inclusion and exclusion criteria as well as diagnostic criteria have been described previously. As for ADNI, amyloid-positive individuals were grouped as preclinical AD (i.e., CN) or AD clinical syndrome (i.e., MCI and Dementia). All participants provided written informed consent prior to study inclusion. Ethical approval was provided by the ethics committee at Lund University, Sweden. Imaging procedures were approved by the Radiation protection committee at Skåne University Hospital and by the Swedish Medical Products Agency. All study relevant covariates are described in Table 1.

MRI and PET acquisition and preprocessing in ADNI

All ADNI structural MRI data were obtained on 3T scanners, using a 3D T1-weighted MPRAGE sequence with 1 mm isotropic voxel-size (TR = 2300 ms, for parameter details see: https://adni.loni.usc.edu/wp-content/uploads/2017/07/ADNI3-MRI-protocols.pdf). Subject-level 3T resting-state fMRI data was included for 77 individuals with an available resting-state fMRI scan within 1 year of the baseline tau-PET scan (3T EPI sequence, TR/TE/flip angle: 3000/30 ms/90°, 200 volumes, 3.4 mm isotropic voxel-resolution). PET data were acquired at standardized time-intervals post injection of 18F-labeled tracers (Flortaucipir: 6 × 5 min time-frames, 75–105 min post injection; Florbetapir: 4 × 5 min time-frames, 50–70 min post injection; Florbetaben: 4 × 5 min time-frames, 90–110 min post injection; further details can be found at http://adni.loni.usc.edu/methods/pet-analysis-method/pet-
analysis). Dynamically acquired images were realigned and averaged to obtain single Flortaucipir/Florbetapir/Florbetaben images. Structural T1 MRI images were normalized to Montreal Neurological Institute (MNI) standard space using Advanced Normalization Tools (ANTS)\(^79\). PET images were then coregistered to native-space T1 images, and subsequently normalized to MNI space by applying the ANTs normalization parameters. From each spatially normalized PET image, we then extracted mean values of 200 ROIs covering the entire neocortex, using an established brain parcellation (see Fig. 1A)\(^39\). For exploratory reasons, we added two pre-established hippocampal ROIs (i.e., left vs. right) to this brain parcellation, which exclude the choroid plexus to allow quantification of hippocampal tau-PET while minimizing the bias included by off-target binding in the choroid plexus\(^41\). To tailor all ROIs to the current sample, we additionally masked all ROIs with a group-specific gray matter mask binarized at a probability of 0.3. For 77 subjects with available resting-state fMRI, we first applied motion correction (i.e., realignment), regressed out the mean signal from the white matter, cerebrospinal fluid as well as the 6 motion parameters that were estimated during realignment (i.e., 3 translations and 3 rotations). Next we applied detrending, band-pass filtering (0.01–0.08 Hz) and despiking. To further eliminate motion artifacts, we performed scrubbing, i.e., removal of high-motion frames as defined by exceeding 0.5 mm framewise displacement. Specifically, high-motion volumes together with one preceding and two subsequent volumes were replaced with zero-padded volumes to eliminate high-motion volumes but keep the number of volumes consistent across subjects. We applied the Schaefer 200 ROI atlas plus the two hippocampal ROIs and extracted mean ROI timeseries, which were cross-correlated and Fisher-\(z\) transformed in order to determine functional connectivity for each subject. The 1000 subject-specific functional connectivity matrices were subsequently averaged and thresholded to a density of 30%. The resulting thresholded functional connectivity matrix was then converted to distance (i.e., shortest path-length between ROIs, Fig. 1B)\(^44\) and we obtained the average distance of a given ROI to the remaining ROIs as a measure of node degree or global connectivity (Fig. 1C). The resulting connectivity map was then scaled between –1 (i.e., high average distance, non-hub) and 1 (i.e., low average distance, hub) to determine a scaled hub map that was later applied to tau-PET data (see below, Fig. 1D). This scaled hub map was determined either including or excluding the two hippocampal ROIs. Note that we did not perform global signal regression due to some controversies about potential bias introduced by this preprocessing step\(^50\). However, when reanalyzing the data with global signal regression, all results presented in this manuscript remained consistent.

For ADNI participants with available resting-state fMRI data, we used the same above-described approach in order to determine subject-level scaled hub maps.

Transforming tau-PET SUVRs to tau positivity and longitudinal tau-PET change

\(^{18}\)F-Flortaucipir tau-PET shows considerable off-target binding across the brain, causing signal in brain regions which do not harbor pathological tau\(^82\). To minimize the impact of off-target binding, we performed our previously established approach that applies Gaussian-mixture modeling to tau-PET data in order to separate target from off-target binding\(^13\).\(^33\)\(^\text{a}\)\(^\text{b}\)\(^\text{c}\)\(^\text{d}\)\(^\text{e}\). The rationale is that many AD individuals and healthy controls should not show pathological tau in most brain regions, hence pathological tau-PET signal should show a skewed distribution. In contrast, off-target binding should be unpecific and thus show a normal distribution. A mixture of target and off-target signal should thus result in a bimodal distribution which can be separated using Gaussian-mixture modeling. To separate target from off-target tau-PET signal, we extracted tau-PET SUVRs of the 200 ROIs included in the brain atlas (Fig. 1A)\(^44\) plus the two hippocampal ROIs\(^13\) and applied Gaussian-mixture modeling to ROI-specific tau-PET values across the ADNI or BioFINDER sample (Fig. 1E). We fitted one- and two-component models and determined the model with the best fit using Akaike's information criterion, revealing a better two-component fit for all ROIs within both samples. For each subject and ROI, we then determined the probability of falling on the right-most distribution of the two fitted Gaussians. Since this right-most distribution is characterized by significant off-target binding, the probability score expresses the proximity of a subject to the pathological distribution, which can thus be interpreted as a probabilistic measure of tau positivity. This probabilistic measure was then multiplied with the actual tau-PET SUVR in order to obtain an SUVR score that was cleaned from off-target signal (Fig. 1F). To determine longitudinal tau-PET changes, we fitted linear mixed models with tau-PET positivity scores as the dependent variable and time (i.e., years from baseline) as the independent variable, controlling for random slope and intercept\(^53\)\(^\text{f}\). From these models, we derived a slope estimate for tau-PET positivity change per year for each subject and ROI. A global tau accumulation rate was calculated as the mean of annual tau-PET positivity change across all ROIs either in- or excluding the two hippocampal ROIs.

Mapping tau-PET patterns to the scaled hub map

In order to determine whether individual tau-PET patterns resembled a hub-like or non-hub-like pattern (Fig. 1C), we mapped tau patterns to...
the connectivity-based scaled hub map (Fig. 1D) that ranges between 1 (i.e., hubs) and −1 (i.e., non-hubs). To this end, we vectorized ROI-based subject-specific tau positivity values (Fig. 1G) and the hub gradient (Fig. 1H) and performed element wise multiplication to determine hub-weighted positivity values (Fig. 1I). By multiplying tau positivity values with the scaled hub map (Fig. 1D), tau in hub regions will be assigned a positive weight, while tau in non-hub regions will be assigned a negative weight. We then assessed the average hub-weighted tau positivity (Fig. 1J), where positive values indicate a stronger tau in hub regions, whereas negative values indicate stronger tau in non-hub regions. In addition, we computed the global mean tau positivity (Fig. 1K), which was used to adjust the mean hub-weighted tau positivity for global tau, yielding the subject-specific tau hub ratio (Fig. 1L, M). Equation 1 summarizes the approach to map an individual tau-PET pattern to the scaled hub map, where $i$ is the index of a given ROI from 1 to 200:

$$\text{tau hub ratio} = \frac{\sum_{i=1}^{200} (\text{tau positivity}_i \times \text{scaled hub}_i)}{\sum_{i=1}^{200} (\text{tau positivity}_i)}$$

Note that the same equation was used in ADNI participants with available resting-state fMRI data, using subject-level connectivity data.

Statistical analysis

For both samples, baseline demographics were compared between diagnostic groups within the ADNI and the BioFINDER sample using chi-squared tests for categorical variables and ANOVAs for continuous variables. In a first step, we performed linear regression to test the association between age and the tau hub ratio, stratified by clinical status (i.e., preclinical vs. symptomatic AD). Models were controlled for sex and education in preclinical AD, and additionally for diagnosis (i.e., MCI or dementia) in symptomatic AD groups. Next, we determined the epicenters of tau pathology for each subject (i.e., 10% of ROIs with highest baseline tau-PET positivity), and computed the mean connectivity-based distance within the epicenter ROIs as a measure of epicenter hub-ness. Using linear regression stratified by clinical status, we then tested whether younger age was associated with a shorter global connectivity-based distance (i.e., higher hub-ness) of tau epicenters, controlling for sex and education (and diagnosis in symptomatic AD). In symptomatic AD subjects of the ADNI cohort, the above-described models were re-ran with actual ages of symptom onset which were available in $n=77$ symptomatic ADNI subjects, while additionally controlling for the time difference between the actual age of onset and the baseline tau-PET scan. In a next step, we tested whether younger age was associated with a faster annual tau accumulation rate (i.e., average annual rate of change in tau-PET positivity across all 200 cortical ROIs), using linear regression controlling for sex, education (and diagnosis in symptomatic AD). Equivalent models were run using the tau hub ratio as a predictor of annual tau accumulation rates to test whether a stronger tau in hubs is associated with faster tau spreading. All above models were additionally run 1000 times using tau hub ratios which were created using randomly shuffled connectivity values as null-models. The true beta values determined on the models using the actual tau hub ratio were then compared against 1000 beta values derived from shuffled tau hub ratio models using an exact test.

To further test whether the deposition pattern rather than the overall severity of tau was associated with younger age and a faster rate of tau accumulation in symptomatic AD, we performed a sliding-window analysis. Specifically, we sorted our sample from low to high global tau-PET levels (i.e., the average tau-PET positivity across the entire cortex). We then used a window size of 30% of the entire AD+ sample, which was shifted in steps of 3 subjects from low to high global tau-PET levels. Within each window, we quantified the mean annual global tau-PET change for subjects with a higher (i.e., >median) tau hub ratio and in subjects with a low (i.e., <median) tau hub ratio. With this analysis approach, we were able to test whether at a given level of baseline tau levels, a higher tau hub ratio at baseline was associated with faster subsequent tau accumulation, i.e., to specifically determine whether the topographical distribution and not the overall severity of tau in hubs is associated with accelerated tau accumulation. To statistically test this hypothesis, we used linear regression to assess the interaction between baseline global tau-PET positivity (i.e., determined within each sliding-window sample) and the tau hub ratio on annual global tau-PET increases, as well as on age.

Lastly, we conducted bootstrapped mediation analyses using the R-package mediation (Version 4.5.0) in order to test whether the association between younger age and faster tau accumulation rates in symptomatic AD was mediated by a higher tau hub ratio. All paths of the mediation model were controlled for sex, education and diagnosis. Significance of the mediation effect was determined on 10,000 bootstrapping iterations. In order to test whether faster tau accumulation rates were associated with faster cognitive decline in a memory composite (i.e., ADNI-MEM) available in ADNI84, we computed annual change rates in cognition based using the same linear mixed model approach that was used for determining tau accumulation rates. Using linear regression controlling for age, sex and education, we then tested whether faster tau accumulation rates were associated with faster decline in ADNI-MEM. All analyses were computed using R statistical software (r-project.org30). For determining statistical significance, we applied an alpha threshold of 0.05 for all analyses. All regression weights are presented as standardized beta values which were determined using the lm.beta package in R (https://cran.r-project.org/web/packages/lm.beta/lm.beta.pdf).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All data used in this manuscript are publicly available from the ADNI database (adni.loni.usc.edu) upon registration and compliance with the data use agreement. BioFINDER data are available from the principal investigator (O.H.), anonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne, which should be regulated in a material transfer agreement. The data that support the findings of this study are available on reasonable request from the corresponding author. Source data are provided with this paper.

Code availability

An example version of the R code used for the main analysis can be found together with simulated data in the Supplementary (i.e., Supplementary Software 1).

References

1. Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. *Brain* **139**, 1515–1567 (2016).
2. Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. *Nat. Med.* **27**, 871–881 (2021).
3. Smith, R. et al. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. *Brain* **143**, 3805–3819 (2020).
4. Jack, C. R. Jr. et al. Longitudinal tau PET in ageing and Alzheimer’s disease. *Brain* **141**, 1517–1528 (2018).
5. Moller, C. et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiol. Aging 34, 2014–2022 (2013).
6. van der Vlies, A. E. et al. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer’s disease with early onset. Psychol. Med. 39, 1907–1911 (2009).
7. Berwick, C., Cummings, J., Raman, R., Sun, X. & Aisen, P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch. Neurol. 69, 901–905 (2012).
8. Stanley, K. & Walker, Z. Do patients with young onset Alzheimer’s disease deteriorate faster than those with late onset Alzheimer’s disease? A review of the literature. Int. Psychogeriatr. 26, 1945–1953 (2014).
9. Koedam, E. L. et al. Early-onset dementia is associated with higher mortality. Dement. Geriatr. Cogn. Disord. 26, 147–152 (2008).
10. Murray, M. E. et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 10, 785–796 (2011).
11. Reitz, C., Rogaeva, E. & Beecham, G. W. Late-onset vs non-mendelian early-onset Alzheimer disease: a distinction without a difference? Neurot. Genet. 6, e512 (2020).
12. Scholl, M. et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain 140, 2286–2294 (2017).
13. La Joie, R. et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, eaau5732 (2020).
14. Bie1, D. et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res. Ther. 13, 137 (2021).
15. Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961–971 (2021).
16. La Joie, R. et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology 96, e650–e661 (2021).
17. Stage, E. C. Jr. et al. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. Alzheimers Res. Ther. 12, 93 (2020).
18. Charl, A. et al. Tau subtypes of Alzheimer’s disease determined in vivo using florataucipir PET imaging. J. Alzheimers Dis. 71, 1037–1048 (2019).
19. Ossenkoppele, R. et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 16, 335–344 (2020).
20. Franzmeier, N. et al. Resting-state global functional connectivity as a biomarker of cognitive reserve in mild cognitive impairment. Brain Imaging Behav. 11, 368–382 (2017).
21. van den Heuvel, M. P. & Sporns, O. Network hubs in the human brain. Trends Cogn. Sci. 17, 683–696 (2013).
22. Cole, M. W. et al. Multi-task connectivity reveals flexible hubs for adaptive task control. Nat. Neurosci. 16, 1348–1355 (2013).
23. Zanto, T. P. & Gazzaley, A. Fronto-parietal network: flexible hub of cognitive control. Trends Cogn. Sci. 17, 602–603 (2013).
24. Benson, G. et al. Functional connectivity in cognitive control networks mitigates the impact of white matter lesions in the elderly. Alzheimers Res. Ther. 10, 109 (2018).
25. Franzmeier, N. et al. Left frontal cortex connectivity underlies cognitive reserve in prodromal Alzheimer disease. Neurology 88, 1054–1061 (2017).
26. Franzmeier, N. et al. Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease. Brain 141, 1186–1200 (2018).
27. Neitzel, J., Franzmeier, N., Rubinski, A., Ewers, M. & Alzheimer’s Disease Neuroimaging Initiative Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory. Neurology 93, e347–e357 (2019).
28. Cascone, A. D., Langella, S., Sklerov, M. & Dayan, E. Frontoparietal network resilience is associated with protection against cognitive decline in Parkinson’s disease. Commun. Biol. 4, 1021 (2021).
29. Busche, M. A. et al. Tau impairs neural circuits, dominating amyloid-beta effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57–64 (2019).
30. Franzmeier, N. et al. The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Abeta-associated tau accumulation and cognitive decline. Alzheimers Dement. 18, 103–115 (2021).
31. Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085–1092 (2016).
32. Calafate, S. et al. Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep. 11, 1176–1183 (2015).
33. Franzmeier, N. et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease. Sci. Adv. 6, eabd1327 (2020).
34. Franzmeier, N. et al. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Nat. Commun. 11, 347 (2020).
35. Franzmeier, N. et al. Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease. Brain 142, 1093–1107 (2019).
36. Vogel, J. W. et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat. Commun. 11, 2612 (2020).
37. Adams, J. N., Mass, A., Harrison, T. M., Baker, S. L. & Jagust, W. J. Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. Elife 8, e49132 (2019).
38. Lee, W. J. et al. Regional Abeta-tau interactions promote onset and acceleration of Alzheimer’s disease tau spreading. Neuron 110, 1932–1943.e5 (2022).
39. Schaefer, A. et al. Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb Cortex 28, 1–20 (2017).
40. Cole, M. W., Yarkoni, T., Repovs, G., Anticevic, A. & Braver, T. S. Global connectivity of prefrontal cortex predicts cognitive control and intelligence. J. Neurosci. 32, 8986–8999 (2012).
41. Pawlik, D., Leuzy, A., Strandberg, O. & Smith, R. Compensating for choroid plexus based off-target signal in the hippocampus using (18)F-florataucipir PET. Neuroimage 221, 117193 (2020).
42. Mattsson, N. et al. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers Res. Ther. 10, 77 (2018).
43. Franzmeier, N. et al. Resting-state connectivity of the left frontal cortex to the default mode and dorsal attention network supports reserve in mild cognitive impairment. Front. Aging Neurosci. 9, 264 (2017).
44. Scholl, M. et al. PET imaging of Tau deposition in the aging human brain. Neuron 89, 971–982 (2016).
45. Ribavincic, G. D. et al. Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. Brain 133, 512–528 (2010).
46. Ossenkoppele, R. et al. Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement. Brain 135, 2115–2125 (2012).
47. Graff-Radford, J. et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 20, 222–234 (2021).
48. Ewers, M. et al. Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease. Brain 144, 2176–2185 (2021).
49. Franzmeier, N. et al. The left frontal cortex supports reserve in aging by enhancing functional network efficiency. Alzheimers Res. Ther. **10**, 28 (2018).
50. Franzmeier, N. et al. Left frontal hub connectivity during memory performance supports reserve in aging and mild cognitive impairment. J. Alzheimers Dis. **59**, 1381–1392 (2017).
51. van den Heuvel, M. P. & Sporns, O. Rich-club organization of the human connectome. J. Neurosci. Off. J. Soc. Neurosci. **31**, 15775–15786 (2011).
52. Gratton, C., Nomura, E. M., Perez, F. & D’Esposito, M. Focal brain lesions to critical locations cause widespread disruption of the modular organization of the brain. J. Cogn. Neurosci. **24**, 1275–1285 (2012).
53. Aben, H. P. et al. Extent to which network hubs are affected by ischemic stroke predicts cognitive recovery. Stroke **50**, 2768–2774 (2019).
54. Warren, D. E. et al. Network measures predict neuropsychological outcome after brain injury. Proc. Natl Acad. Sci. USA **111**, 14247–14252 (2014).
55. Liu, Y. et al. Impaired long distance functional connectivity and weighted network architecture in Alzheimer’s disease. Cereb. Cortex **24**, 1422–1435 (2014).
56. Chhatwal, J. P. et al. Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing. Brain **141**, 1486–1500 (2018).
57. Kocagencu, E. et al. Tau pathology in early Alzheimer’s disease is linked to selective disruptions in neurophysiological network dynamics. Neurobiol. Aging **92**, 141–152 (2020).
58. Schultz, A. P. et al. Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals. J. Neurosci. **37**, 4323–4331 (2017).
59. Cornblath, E. J. et al. Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. Sci. Adv. **7**, eaba6677 (2021).
60. Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies: still a challenge. Mol. Psychiatry **24**, 1112–1134 (2019).
61. Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. **71**, 1282–1289 (2014).
62. Cole, M. W., Pathak, S. & Schneider, W. Identifying the brain’s most globally connected regions. Neuroimage **49**, 3132–3148 (2010).
63. Schultz, D. H. et al. Global connectivity of the fronto-parietal cognitive control network is related to depression symptoms in the general population. Netw. Neurosci. **3**, 107–123 (2019).
64. Rubinov, M. & Sporns, O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage **52**, 1059–1069 (2010).
65. Stern, Y. et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. **16**, 1305–1311 (2020).
66. Harrison, T. M. et al. Longitudinal tau accumulation and atrophy in ageing and Alzheimer disease. Ann. Neurol. **85**, 229–240 (2019).
67. Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain **142**, 1723–1735 (2019).
68. Grothe, M. J. et al. Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology. Brain **141**, 2755–2771 (2018).
69. Sepulcre, J. et al. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat. Med. **24**, 1910–1918 (2018).
70. Franzmeier, N., Rubinski, A., Neitzel, J., Ewers, M. & The Alzheimer’s Disease Neuroimaging Initiative The BINI n5744373 SNP is associated with increased tau-PET levels and impaired memory. Nat. Commun. **10**, 1766 (2019).
71. Lesman-Seegev, O. H. et al. Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. Neuroimage Clin. **24**, 102025 (2019).
72. Edwards, G. 3rd, Zhao, J., Dash, P. K., Soto, C. & Moreno-Gonzalez, I. Traumatic brain injury induces tau aggregation and spreading. J. Neurotrauma **37**, 80–92 (2020).
73. Finn, E. S. et al. Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. Nat. Neurosci. **18**, 1664–1671 (2015).
74. Franzmeier, N. et al. Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine learning. Alzheimers Dement. **16**, 501–511 (2020).
75. Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. **72**, 578–586 (2012).
76. Klunk, W. E. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. **11**, e1–e14 (2015).
77. Thurfjell, L. et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J. Nucl. Med. **55**, 1623–1628 (2014).
78. Mattsson, N. et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology **90**, e388–e395 (2018).
79. Avants, B. B. et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage **54**, 2033–2044 (2011).
80. Smith, R. et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain **139**, 2372–2379 (2016).
81. Murphy, K. & Fox, M. D. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. Neuroimage **154**, 169–173 (2016).
82. Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez-Vieitez, E. & Nordberg, A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement. **10**, 232–236 (2018).
83. Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med. **25**, 277–283 (2019).
84. Crane, P. K. et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. **6**, 502–516 (2012).

**Acknowledgements**

We acknowledge all members of the Alzheimer’s Disease Neuroimaging Initiative. N.F. received research support from the Hertie Foundation (Network of Excellence in Clinical Neurosciences), O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cereve. The BioFINDER study was supported by the Swedish Research Council, the Knut and Alice Wallenberg foundation, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multi-disciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Parkinson Foundation of Sweden, the Parkinson Research Foundation, the Skåne University Hospital Foundation, and the Swedish federal government under the ALF agreement. Doses of 18F-flutemetamol injection were sponsored by GE Healthcare. The precursor of 18F-flortaucipir was provided by AVID Radiopharmaceuticals. ADNI data collection and sharing for this project was funded by the ADNI (National...
Institutes of Health grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from the following: AbbVie, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Araclon Biotech, BioClinica Inc., Biogen, Bristol-Myers Squibb Company, CereSpir Inc., Cogstate, Eisai Inc., Elan Pharmaceuticals Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd. and its affiliated company Genentech Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research and Development LLC., Johnson & Johnson Pharmaceutical Research and Development LLC., Lumosity, Lundbeck, Merck & Co. Inc., Meso Scale Diagnostics LLC., NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).

Author contributions
L.F.: data analysis, study concept and design, drafting the manuscript; M.E., M.B., R.O., M.D., and O.H.: study concept and design, critical revision of the manuscript; D.B., P.H., A.S., A.D., S.R., A.R., and O.S.: data preprocessing, data analysis, critical revision of the manuscript; K.B., D.J., and A.P.B.: critical revision of the manuscript; R.S. and N.M.C.: data acquisition, critical revision of the manuscript; N.F.: data preprocessing, data analysis, study concept and design, drafting the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Competing interests
The authors declare no competing interests.